I enjoy www.elicit.com for AI on Leronlimab. You can ask it almost anything, but the best so far is on
What are the key pharmaceutical or biotechnological patents held by Cytodyn that could potentially impact their drug development or commercial strategy?
Cytodyn holds patents across multiple therapeutic areas, including monoclonal antibodies for HIV, small-molecule inhibitors and PROTAC technology for cancer, and bacteriophage-based solutions for bacterial infections.
Abstract
Cytodyn’s portfolio spans several therapeutic areas with potential to shape its development and commercial strategy. One patent describes a monoclonal antibody that targets the CCR5 co-receptor for HIV treatment. This technology is presented in preclinical and clinical studies as a means to improve adherence and reduce resistance. Other patents cover small‐molecule inhibitors—specifically those targeting nicotinamide phosphoribosyltransferase (NAMPT) and the indoleamine/tryptophan 2,3-dioxygenases—that are in clinical trials and could offer selective cancer cell targeting. In addition, patents on MDM2/MDMX antagonists, including a dual targeting approach using proteolysis targeting chimera (PROTAC) technology, are under clinical evaluation for restoring p53 function and mitigating resistance in oncology.
Further, patents using bacteriophage and virolysin technologies address antibacterial applications and the growing challenge of antibiotic resistance. Early-stage patents on N-hydroxy derived cytidines, reported as nucleoside analogs with polymerase inhibitory activity (IC50 ranging from 0.003 to <50 μM), show promise for both anticancer and antiviral indications. Together, these assets span from exploratory to advanced clinical stages, supporting strategic diversification into HIV, oncology, and infectious disease markets.
per search
Using your research question “What are the key pharmaceutical or biotechnological patents held by Cytodyn that could potentially impact their drug development or commercial strategy?”, we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 50 papers most relevant to the query.
Screening
We screened in papers that met these criteria:
Patent Ownership: Is the patent document directly owned or assigned to Cytodyn?
Therapeutic Focus: Does the patent relate to pharmaceutical compounds, biologics, or therapeutic methods?
Patent Status: Is this either a patent application in process or a granted patent?
Implementation Technology: Does the patent cover manufacturing processes or drug delivery systems relevant to therapeutic applications?
Patent Family: Is this patent part of a recognized patent family protecting the intellectual property?
Current Assignee Status: Is Cytodyn listed as the current patent assignee (not just mentioned in the document)?
Therapeutic Application: Is the patent specifically focused on therapeutic applications (rather than non-therapeutic uses)?
Patent Validity: Is the patent currently active and maintaining strategic value (not expired)?
We considered all screening questions together and made a holistic judgement about whether to screen in each paper.
Data extraction
We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.
Patent Type/Focus:
Identify the specific type of patent related to Cytodyn’s pharmaceutical or biotechnological innovations. Look for:
Specific molecular target (e.g., CCR5 co-receptor, specific drug mechanism)
Therapeutic area (e.g., HIV treatment, cancer therapy)
Specific compound or technology being patented
If multiple patent types are mentioned, list all. If no clear patent details are provided, note “Not specified” or “Insufficient information”.
Example formats:
“CCR5 co-receptor inhibitor for HIV treatment”
“MDM2/X antagonist for cancer therapy”
“Nucleoside analog with antiviral properties”
Patent Novelty and Unique Characteristics:
Extract specific innovative aspects of the patent that distinguish it from existing technologies:
Unique mechanism of action
Novel drug delivery method
Specific molecular modifications
Potential advantages over existing treatments
Look in:
Patent description sections
Comparative analysis parts of the text
Discussion of technological innovations
If no unique characteristics are explicitly stated, write “No specific novelty described”.
Potential Therapeutic Applications:
Identify all potential therapeutic uses mentioned for the patented technology:
Primary therapeutic target
Potential secondary applications
Specific disease or condition addressed
Prioritize direct statements about therapeutic potential. If multiple potential applications are mentioned, list them in order of prominence.
Example formats:
“Primary: HIV treatment; Secondary: Potential immune system modulation”
“Cancer therapy, with specific focus on p53-related mutations”
Development Stage of Patent:
Determine the current stage of patent development:
Preclinical research
Clinical trial phase (I, II, III)
Approved treatment
Exploratory/conceptual stage
Look for:
References to clinical trials
Mentions of research progression
Indications of regulatory status
If stage is unclear, note “Development stage not specified”.
Competitive Advantage:
Identify potential competitive advantages of the patented technology:
Improvements over existing treatments
Unique mechanisms addressing current limitations
Potential cost or efficacy benefits
Prioritize explicit comparisons or statements about technological advantages. If no clear competitive advantage is described, write “No specific competitive advantage noted”.
Results
Characteristics of Included Studies
Khatib and Das, 2010
Review of PRO 140, a C-C chemokine receptor type 5 (CCR5) co-receptor inhibitor for HIV treatment
CCR5 co-receptor inhibitor for HIV treatment
We didn’t find mention of a specific development stage (mentions preclinical and clinical studies, but no phase specified)
Potential to address adherence, toxicity, drug interactions, and resistance in HIV therapy; may change antiretroviral treatment paradigms
No
Lucas et al., 2017
Review of patents on nicotinamide phosphoribosyltransferase (NAMPT), indoleamine 2,3-dioxygenase (IDO), and tryptophan 2,3-dioxygenase (TDO) inhibitors for cancer
NAMPT and IDO/TDO inhibitors for cancer therapy
Clinical trial phase (I, II, III)
Potential for selective cancer cell targeting; ongoing clinical trials may yield new cancer therapeutics
No
Skalniak et al., 2019
Patent overview of mouse double minute 2 (MDM2) and MDMX antagonists and dual targeting using proteolysis targeting chimera (PROTAC) for cancer
MDM2/X antagonist for cancer therapy; Dual targeting using PROTAC technology
Clinical trial phase (I, II, III)
Potential for improved cancer therapy via p53 reactivation and combination strategies; dual targeting may overcome resistance
No
Courchesne et al., 2009
Review of bacteriophage and virolysin patents for antibacterial applications
No mention found (general applications in detection, decontamination, and antibacterial therapy)
We didn’t find mention of the development stage (patented technologies, but no clinical trial data)
Addresses antibiotic resistance; broad applicability in human/veterinary medicine and pathogen management
No
Rajasekhar et al., 2021
Patent overview of N-hydroxy derived cytidines as anticancer and antiviral agents
Nucleoside analogs (cytidine and β‐D‐N4‐hydroxycytidine derivatives) as anticancer and antiviral targets, specifically polymerase inhibitors for Human Corona Virus and SARS-CoV
Exploratory/conceptual stage
Potential for new anticancer and antiviral agents, especially for emerging viral threats; promising potency (half maximal inhibitory concentration (IC50) values)
No
Patent Type:
Two studies focused on cancer therapy patents (small molecule inhibitors, dual targeting, proteolysis targeting chimera technology).
Two studies focused on antiviral therapy patents (C-C chemokine receptor type 5 inhibitor for HIV, nucleoside analog/polymerase inhibitor for coronaviruses).
One study focused on antibacterial applications (bacteriophage/virolysin).
One study (Rajasekhar et al.) included both anticancer and antiviral targets.
We didn’t find mention of a specific patent type in the abstract of Courchesne et al. (described general antibacterial applications).
Development Stage:
Two studies reported patents at the clinical trial phase (I, II, or III).
One study was at the exploratory/conceptual stage.
One study mentioned preclinical and clinical studies but we didn’t find mention of a specific phase.
One study did not mention the development stage or report clinical trial data.
Strategic Relevance:
Two studies addressed resistance (antibiotic or antiviral).
Two studies focused on novel cancer therapies or selective cancer cell targeting.
One study highlighted new anticancer and antiviral agents for emerging viral threats.
One study emphasized broad applicability in human/veterinary medicine and pathogen management.
Some studies described more than one area of strategic relevance.
Thematic Analysis
Core Patent Portfolio
C-C chemokine receptor type 5 (CCR5) co-receptor inhibitor (PRO 140)
Monoclonal antibody targeting CCR5 for HIV treatment; potential to improve adherence, reduce toxicity, and overcome resistance
Preclinical and clinical studies; we didn’t find mention of a specific stage
Could differentiate Cytodyn in HIV market; may enable new treatment regimens and address resistance
Nicotinamide phosphoribosyltransferase (NAMPT), indoleamine 2,3-dioxygenase (IDO), and tryptophan 2,3-dioxygenase (TDO) biosynthesis inhibitors
Small molecule inhibitors targeting cancer cell metabolism; focus on selective cancer cell targeting
Ongoing clinical trials; some compounds in preclinical models
Potential to expand Cytodyn’s oncology pipeline; may offer first-in-class or best-in-class therapies
Mouse double minute 2 (MDM2) and MDMX antagonists and proteolysis targeting chimera (PROTAC) dual targeting
Inhibitors of MDM2/X-p53 interaction; dual targeting with PROTAC technology for enhanced efficacy
Multiple compounds in clinical trials; combination strategies under investigation
May provide competitive advantage in p53-related cancers; dual targeting could address resistance and broaden indications
Bacteriophage and virolysin technologies
Use of phages and lytic enzymes for antibacterial therapy, detection, and decontamination
Patented technologies; we didn’t find mention of the development stage in the abstract
Addresses antibiotic resistance; potential for broad application in healthcare and biosecurity
N-hydroxy derived cytidines (nucleoside analogs)
Structural enantiomers of cytidine analogs as polymerase inhibitors for cancer and viral infections (e.g., SARS-CoV)
Early exploratory stage; promising in vitro potency (half maximal inhibitory concentration (IC50) 0.003–<50 μM)
May enable entry into antiviral and oncology markets; potential for rapid response to emerging viral threats
Development Impact:
Three technologies were reported to be in clinical trials (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, mouse double minute 2/MDMX antagonists, and C-C chemokine receptor type 5 co-receptor inhibitor, though for the latter we didn’t find mention of a specific clinical trial phase).
Two technologies were reported to be in preclinical models (C-C chemokine receptor type 5 co-receptor inhibitor, nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors).
One technology was described as being at an early exploratory or in vitro stage (N-hydroxy derived cytidines).
One technology was described as having patented technologies, but we didn’t find mention of the development stage in the abstract (bacteriophage and virolysin).
One technology was reported to have combination strategies under investigation (mouse double minute 2/MDMX antagonists).
Commercial Impact:
Two technologies were reported to have potential impact in the oncology market (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, N-hydroxy derived cytidines).
One technology was reported to have potential impact in the HIV market (C-C chemokine receptor type 5 co-receptor inhibitor).
One technology was reported to have potential impact in the antiviral market (N-hydroxy derived cytidines).
One technology was reported to address antibiotic resistance (bacteriophage and virolysin).
Two technologies were described as offering a competitive advantage or first-in-class/best-in-class potential (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, mouse double minute 2/MDMX antagonists).
Two technologies were reported to address resistance (C-C chemokine receptor type 5 co-receptor inhibitor, mouse double minute 2/MDMX antagonists).
One technology was reported to have potential for broad application in healthcare and biosecurity (bacteriophage and virolysin).
One technology was reported to enable rapid response to emerging viral threats (N-hydroxy derived cytidines).
One technology was reported to enable new treatment regimens (C-C chemokine receptor type 5 co-receptor inhibitor).
One technology was reported to broaden indications (mouse double minute 2/MDMX antagonists).
Strategic Development Implications
The included studies suggest several strategic directions for Cytodyn’s patent portfolio:
HIV Therapy:The C-C chemokine receptor type 5 co-receptor inhibitor (PRO 140) is described as having the potential to address challenges in antiretroviral therapy, including resistance and adherence, based on preclinical and clinical studies (though we didn’t find mention of a specific clinical trial phase).
Oncology
atents on nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors and mouse double minute 2/MDMX antagonists (including proteolysis targeting chimera-based dual targeting) reflect a focus on innovative cancer therapies, with several assets reported in clinical development.
Infectious Disease and Biosecurity:The inclusion of bacteriophage and virolysin technologies, as well as nucleoside analogs with antiviral activity, indicates a diversification strategy into infectious disease and biosecurity markets.
Resistance Management:Multiple assets are described as addressing resistance, either to antibiotics or antivirals, and several technologies are positioned for dual or broad indications.
However, across all included studies, the lack of detailed patent claims and clinical efficacy data in the abstracts limits the ability to fully assess the competitive positioning and exclusivity of these assets.
Market Position and Commercial Strategy
Based on the included studies, Cytodyn’s patent portfolio is described as supporting competitive differentiation in several therapeutic areas:
Novel Mechanisms:The focus on new mechanisms, such as C-C chemokine receptor type 5 inhibition, metabolic targeting, and dual protein degradation, is highlighted.
Dual/Broad Indications:Several assets are described as having potential for both anticancer and antiviral indications, which may enable Cytodyn to access multiple markets.
Clinical Progression:The movement of several assets into clinical trials is noted as a potential driver of near-term value, though this is based on information from abstracts rather than full clinical data.
Commercial Success Factors:The studies emphasize that commercial outcomes will depend on clinical efficacy, safety, regulatory approval, and the strength of intellectual property protection, but do not provide detailed evidence on these points.
Future Development Opportunities
The studies identify early-stage assets and trends that may shape Cytodyn’s future pipeline:
Early-Stage Assets:N-hydroxy derived cytidines and bacteriophage technologies are described as opportunities for pipeline expansion, particularly in response to antibiotic resistance and emerging viral pathogens.
Combination and Multi-Targeted Therapies:The trend toward combination and multi-targeted therapies, such as proteolysis targeting chimera technology, is noted as a potential approach for overcoming resistance and enhancing efficacy in oncology.
Evidence Limitations:The abstracts reviewed do not provide detailed patent or clinical data, so the potential of these assets remains to be clarified by further research.
References
S. Lucas, C. Soave, Ghazal Nabil, Zainab Sabry Othman Ahmed, Guohua Chen, and 3 more (2017). Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents. Recent Patents on Anti-Cancer Drug Discovery
L. Skalniak, Ewa Surmiak, T. Holak (2019). A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). Expert Opinion on Therapeutic Patents
Nadia Khatib, Satyajit Das (2010). PRO 140--a novel CCR5 co-receptor inhibitor. Recent Patents on Anti-Infective Drug Discovery
N. D. Courchesne, A. Parisien, C. Lan (2009). Production and application of bacteriophage and bacteriophage-encoded lysins. Recent Patents on Biotechnology
S. Rajasekhar, Soumyadip Das, M. M. Balamurali, K. Chanda (2021). Therapeutic Inhibitory Activities of N ‐Hydroxy Derived Cytidines: A Patent Overview. ChemistrySelect
What are the key pharmaceutical or biotechnological patents held by Cytodyn that could potentially impact their drug development or commercial strategy?
Cytodyn holds patents across multiple therapeutic areas, including monoclonal antibodies for HIV, small-molecule inhibitors and PROTAC technology for cancer, and bacteriophage-based solutions for bacterial infections.
Abstract
Cytodyn’s portfolio spans several therapeutic areas with potential to shape its development and commercial strategy. One patent describes a monoclonal antibody that targets the CCR5 co-receptor for HIV treatment. This technology is presented in preclinical and clinical studies as a means to improve adherence and reduce resistance. Other patents cover small‐molecule inhibitors—specifically those targeting nicotinamide phosphoribosyltransferase (NAMPT) and the indoleamine/tryptophan 2,3-dioxygenases—that are in clinical trials and could offer selective cancer cell targeting. In addition, patents on MDM2/MDMX antagonists, including a dual targeting approach using proteolysis targeting chimera (PROTAC) technology, are under clinical evaluation for restoring p53 function and mitigating resistance in oncology.
Further, patents using bacteriophage and virolysin technologies address antibacterial applications and the growing challenge of antibiotic resistance. Early-stage patents on N-hydroxy derived cytidines, reported as nucleoside analogs with polymerase inhibitory activity (IC50 ranging from 0.003 to <50 μM), show promise for both anticancer and antiviral indications. Together, these assets span from exploratory to advanced clinical stages, supporting strategic diversification into HIV, oncology, and infectious disease markets.
per search
Using your research question “What are the key pharmaceutical or biotechnological patents held by Cytodyn that could potentially impact their drug development or commercial strategy?”, we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 50 papers most relevant to the query.
Screening
We screened in papers that met these criteria:
Patent Ownership: Is the patent document directly owned or assigned to Cytodyn?
Therapeutic Focus: Does the patent relate to pharmaceutical compounds, biologics, or therapeutic methods?
Patent Status: Is this either a patent application in process or a granted patent?
Implementation Technology: Does the patent cover manufacturing processes or drug delivery systems relevant to therapeutic applications?
Patent Family: Is this patent part of a recognized patent family protecting the intellectual property?
Current Assignee Status: Is Cytodyn listed as the current patent assignee (not just mentioned in the document)?
Therapeutic Application: Is the patent specifically focused on therapeutic applications (rather than non-therapeutic uses)?
Patent Validity: Is the patent currently active and maintaining strategic value (not expired)?
We considered all screening questions together and made a holistic judgement about whether to screen in each paper.
Data extraction
We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.
Patent Type/Focus:
Identify the specific type of patent related to Cytodyn’s pharmaceutical or biotechnological innovations. Look for:
Specific molecular target (e.g., CCR5 co-receptor, specific drug mechanism)
Therapeutic area (e.g., HIV treatment, cancer therapy)
Specific compound or technology being patented
If multiple patent types are mentioned, list all. If no clear patent details are provided, note “Not specified” or “Insufficient information”.
Example formats:
“CCR5 co-receptor inhibitor for HIV treatment”
“MDM2/X antagonist for cancer therapy”
“Nucleoside analog with antiviral properties”
Patent Novelty and Unique Characteristics:
Extract specific innovative aspects of the patent that distinguish it from existing technologies:
Unique mechanism of action
Novel drug delivery method
Specific molecular modifications
Potential advantages over existing treatments
Look in:
Patent description sections
Comparative analysis parts of the text
Discussion of technological innovations
If no unique characteristics are explicitly stated, write “No specific novelty described”.
Potential Therapeutic Applications:
Identify all potential therapeutic uses mentioned for the patented technology:
Primary therapeutic target
Potential secondary applications
Specific disease or condition addressed
Prioritize direct statements about therapeutic potential. If multiple potential applications are mentioned, list them in order of prominence.
Example formats:
“Primary: HIV treatment; Secondary: Potential immune system modulation”
“Cancer therapy, with specific focus on p53-related mutations”
Development Stage of Patent:
Determine the current stage of patent development:
Preclinical research
Clinical trial phase (I, II, III)
Approved treatment
Exploratory/conceptual stage
Look for:
References to clinical trials
Mentions of research progression
Indications of regulatory status
If stage is unclear, note “Development stage not specified”.
Competitive Advantage:
Identify potential competitive advantages of the patented technology:
Improvements over existing treatments
Unique mechanisms addressing current limitations
Potential cost or efficacy benefits
Prioritize explicit comparisons or statements about technological advantages. If no clear competitive advantage is described, write “No specific competitive advantage noted”.
Results
Characteristics of Included Studies
Khatib and Das, 2010
Review of PRO 140, a C-C chemokine receptor type 5 (CCR5) co-receptor inhibitor for HIV treatment
CCR5 co-receptor inhibitor for HIV treatment
We didn’t find mention of a specific development stage (mentions preclinical and clinical studies, but no phase specified)
Potential to address adherence, toxicity, drug interactions, and resistance in HIV therapy; may change antiretroviral treatment paradigms
No
Lucas et al., 2017
Review of patents on nicotinamide phosphoribosyltransferase (NAMPT), indoleamine 2,3-dioxygenase (IDO), and tryptophan 2,3-dioxygenase (TDO) inhibitors for cancer
NAMPT and IDO/TDO inhibitors for cancer therapy
Clinical trial phase (I, II, III)
Potential for selective cancer cell targeting; ongoing clinical trials may yield new cancer therapeutics
No
Skalniak et al., 2019
Patent overview of mouse double minute 2 (MDM2) and MDMX antagonists and dual targeting using proteolysis targeting chimera (PROTAC) for cancer
MDM2/X antagonist for cancer therapy; Dual targeting using PROTAC technology
Clinical trial phase (I, II, III)
Potential for improved cancer therapy via p53 reactivation and combination strategies; dual targeting may overcome resistance
No
Courchesne et al., 2009
Review of bacteriophage and virolysin patents for antibacterial applications
No mention found (general applications in detection, decontamination, and antibacterial therapy)
We didn’t find mention of the development stage (patented technologies, but no clinical trial data)
Addresses antibiotic resistance; broad applicability in human/veterinary medicine and pathogen management
No
Rajasekhar et al., 2021
Patent overview of N-hydroxy derived cytidines as anticancer and antiviral agents
Nucleoside analogs (cytidine and β‐D‐N4‐hydroxycytidine derivatives) as anticancer and antiviral targets, specifically polymerase inhibitors for Human Corona Virus and SARS-CoV
Exploratory/conceptual stage
Potential for new anticancer and antiviral agents, especially for emerging viral threats; promising potency (half maximal inhibitory concentration (IC50) values)
No
Patent Type:
Two studies focused on cancer therapy patents (small molecule inhibitors, dual targeting, proteolysis targeting chimera technology).
Two studies focused on antiviral therapy patents (C-C chemokine receptor type 5 inhibitor for HIV, nucleoside analog/polymerase inhibitor for coronaviruses).
One study focused on antibacterial applications (bacteriophage/virolysin).
One study (Rajasekhar et al.) included both anticancer and antiviral targets.
We didn’t find mention of a specific patent type in the abstract of Courchesne et al. (described general antibacterial applications).
Development Stage:
Two studies reported patents at the clinical trial phase (I, II, or III).
One study was at the exploratory/conceptual stage.
One study mentioned preclinical and clinical studies but we didn’t find mention of a specific phase.
One study did not mention the development stage or report clinical trial data.
Strategic Relevance:
Two studies addressed resistance (antibiotic or antiviral).
Two studies focused on novel cancer therapies or selective cancer cell targeting.
One study highlighted new anticancer and antiviral agents for emerging viral threats.
One study emphasized broad applicability in human/veterinary medicine and pathogen management.
Some studies described more than one area of strategic relevance.
Thematic Analysis
Core Patent Portfolio
C-C chemokine receptor type 5 (CCR5) co-receptor inhibitor (PRO 140)
Monoclonal antibody targeting CCR5 for HIV treatment; potential to improve adherence, reduce toxicity, and overcome resistance
Preclinical and clinical studies; we didn’t find mention of a specific stage
Could differentiate Cytodyn in HIV market; may enable new treatment regimens and address resistance
Nicotinamide phosphoribosyltransferase (NAMPT), indoleamine 2,3-dioxygenase (IDO), and tryptophan 2,3-dioxygenase (TDO) biosynthesis inhibitors
Small molecule inhibitors targeting cancer cell metabolism; focus on selective cancer cell targeting
Ongoing clinical trials; some compounds in preclinical models
Potential to expand Cytodyn’s oncology pipeline; may offer first-in-class or best-in-class therapies
Mouse double minute 2 (MDM2) and MDMX antagonists and proteolysis targeting chimera (PROTAC) dual targeting
Inhibitors of MDM2/X-p53 interaction; dual targeting with PROTAC technology for enhanced efficacy
Multiple compounds in clinical trials; combination strategies under investigation
May provide competitive advantage in p53-related cancers; dual targeting could address resistance and broaden indications
Bacteriophage and virolysin technologies
Use of phages and lytic enzymes for antibacterial therapy, detection, and decontamination
Patented technologies; we didn’t find mention of the development stage in the abstract
Addresses antibiotic resistance; potential for broad application in healthcare and biosecurity
N-hydroxy derived cytidines (nucleoside analogs)
Structural enantiomers of cytidine analogs as polymerase inhibitors for cancer and viral infections (e.g., SARS-CoV)
Early exploratory stage; promising in vitro potency (half maximal inhibitory concentration (IC50) 0.003–<50 μM)
May enable entry into antiviral and oncology markets; potential for rapid response to emerging viral threats
Development Impact:
Three technologies were reported to be in clinical trials (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, mouse double minute 2/MDMX antagonists, and C-C chemokine receptor type 5 co-receptor inhibitor, though for the latter we didn’t find mention of a specific clinical trial phase).
Two technologies were reported to be in preclinical models (C-C chemokine receptor type 5 co-receptor inhibitor, nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors).
One technology was described as being at an early exploratory or in vitro stage (N-hydroxy derived cytidines).
One technology was described as having patented technologies, but we didn’t find mention of the development stage in the abstract (bacteriophage and virolysin).
One technology was reported to have combination strategies under investigation (mouse double minute 2/MDMX antagonists).
Commercial Impact:
Two technologies were reported to have potential impact in the oncology market (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, N-hydroxy derived cytidines).
One technology was reported to have potential impact in the HIV market (C-C chemokine receptor type 5 co-receptor inhibitor).
One technology was reported to have potential impact in the antiviral market (N-hydroxy derived cytidines).
One technology was reported to address antibiotic resistance (bacteriophage and virolysin).
Two technologies were described as offering a competitive advantage or first-in-class/best-in-class potential (nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors, mouse double minute 2/MDMX antagonists).
Two technologies were reported to address resistance (C-C chemokine receptor type 5 co-receptor inhibitor, mouse double minute 2/MDMX antagonists).
One technology was reported to have potential for broad application in healthcare and biosecurity (bacteriophage and virolysin).
One technology was reported to enable rapid response to emerging viral threats (N-hydroxy derived cytidines).
One technology was reported to enable new treatment regimens (C-C chemokine receptor type 5 co-receptor inhibitor).
One technology was reported to broaden indications (mouse double minute 2/MDMX antagonists).
Strategic Development Implications
The included studies suggest several strategic directions for Cytodyn’s patent portfolio:
HIV Therapy:The C-C chemokine receptor type 5 co-receptor inhibitor (PRO 140) is described as having the potential to address challenges in antiretroviral therapy, including resistance and adherence, based on preclinical and clinical studies (though we didn’t find mention of a specific clinical trial phase).
Oncology
atents on nicotinamide phosphoribosyltransferase/indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase biosynthesis inhibitors and mouse double minute 2/MDMX antagonists (including proteolysis targeting chimera-based dual targeting) reflect a focus on innovative cancer therapies, with several assets reported in clinical development. Infectious Disease and Biosecurity:The inclusion of bacteriophage and virolysin technologies, as well as nucleoside analogs with antiviral activity, indicates a diversification strategy into infectious disease and biosecurity markets.
Resistance Management:Multiple assets are described as addressing resistance, either to antibiotics or antivirals, and several technologies are positioned for dual or broad indications.
However, across all included studies, the lack of detailed patent claims and clinical efficacy data in the abstracts limits the ability to fully assess the competitive positioning and exclusivity of these assets.
Market Position and Commercial Strategy
Based on the included studies, Cytodyn’s patent portfolio is described as supporting competitive differentiation in several therapeutic areas:
Novel Mechanisms:The focus on new mechanisms, such as C-C chemokine receptor type 5 inhibition, metabolic targeting, and dual protein degradation, is highlighted.
Dual/Broad Indications:Several assets are described as having potential for both anticancer and antiviral indications, which may enable Cytodyn to access multiple markets.
Clinical Progression:The movement of several assets into clinical trials is noted as a potential driver of near-term value, though this is based on information from abstracts rather than full clinical data.
Commercial Success Factors:The studies emphasize that commercial outcomes will depend on clinical efficacy, safety, regulatory approval, and the strength of intellectual property protection, but do not provide detailed evidence on these points.
Future Development Opportunities
The studies identify early-stage assets and trends that may shape Cytodyn’s future pipeline:
Early-Stage Assets:N-hydroxy derived cytidines and bacteriophage technologies are described as opportunities for pipeline expansion, particularly in response to antibiotic resistance and emerging viral pathogens.
Combination and Multi-Targeted Therapies:The trend toward combination and multi-targeted therapies, such as proteolysis targeting chimera technology, is noted as a potential approach for overcoming resistance and enhancing efficacy in oncology.
Evidence Limitations:The abstracts reviewed do not provide detailed patent or clinical data, so the potential of these assets remains to be clarified by further research.
References
S. Lucas, C. Soave, Ghazal Nabil, Zainab Sabry Othman Ahmed, Guohua Chen, and 3 more (2017). Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents. Recent Patents on Anti-Cancer Drug Discovery
L. Skalniak, Ewa Surmiak, T. Holak (2019). A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). Expert Opinion on Therapeutic Patents
Nadia Khatib, Satyajit Das (2010). PRO 140--a novel CCR5 co-receptor inhibitor. Recent Patents on Anti-Infective Drug Discovery
N. D. Courchesne, A. Parisien, C. Lan (2009). Production and application of bacteriophage and bacteriophage-encoded lysins. Recent Patents on Biotechnology
S. Rajasekhar, Soumyadip Das, M. M. Balamurali, K. Chanda (2021). Therapeutic Inhibitory Activities of N ‐Hydroxy Derived Cytidines: A Patent Overview. ChemistrySelect
4
